Pemetrexed Pfizer (previously Pemetrexed Hospira) Euroopa Liit - eesti - EMA (European Medicines Agency)

pemetrexed pfizer (previously pemetrexed hospira)

pfizer europe ma eeig - pemetrexed disodium, pemetrexed disodium hemipentahydrate - carcinoma, non-small-cell lung; mesothelioma - antineoplastilised ained - malignant pleural mesotheliomapemetrexed pfizer in combination with cisplatin is indicated for the treatment of chemotherapy naïve patients with unresectable malignant pleural mesothelioma. non-small cell lung cancerpemetrexed pfizer in combination with cisplatin is indicated for the first-line treatment of patients with locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology. pemetrexed pfizer is indicated as monotherapy for the maintenance treatment of locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology in patients whose disease has not progressed immediately following platinum-based chemotherapy. pemetrexed pfizer is indicated as monotherapy for the second-line treatment of patients with locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology.

Pemetrexed Baxter Euroopa Liit - eesti - EMA (European Medicines Agency)

pemetrexed baxter

baxter holding b.v. - pemetrexed disodium heptahydrate - carcinoma, non-small-cell lung; mesothelioma - antineoplastilised ained - malignant pleural mesotheliomapemetrexed baxter in combination with cisplatin is indicated for the treatment of chemotherapy naïve patients with unresectable malignant pleural mesothelioma. non-small cell lung cancerpemetrexed baxter in combination with cisplatin is indicated for the first line treatment of patients with locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology (see section 5. pemetrexed baxter is indicated as monotherapy for the maintenance treatment of locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology in patients whose disease has not progressed immediately following platinum-based chemotherapy (see section 5. pemetrexed baxter is indicated as monotherapy for the second line treatment of patients with locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology (see section 5.

Ytracis Euroopa Liit - eesti - EMA (European Medicines Agency)

ytracis

cis bio international - yttrium (90y) chloride - radionukliidi pildistamine - diagnostilised radiofarmatseutilised ühendid - kasutada ainult spetsiaalselt välja töötatud ja radioloogilise märgistamise jaoks selle radionukliidiga kandev-molekulide radiomärgistamiseks. radiopharmaceutical precursor - not intended for direct application to patients.

Mistral® 700 WG Eesti - eesti - Adama

mistral® 700 wg

adama - vees dispergeeruvad graanulid - metribusiin - herbitsiidid

SODIUM CHLORIDE B. BRAUN 0,9% infusioonilahus Eesti - eesti - Ravimiamet

sodium chloride b. braun 0,9% infusioonilahus

b. braun melsungen ag - naatriumkloriid - infusioonilahus - 0,9% 50ml 20tk; 0,9% 100ml 20tk; 0,9% 250ml 10tk; 0,9% 1000ml 10tk; 0,9% 500ml 10tk

SODIUM CHLORIDE KABI 0,9% süsteravimi lahusti Eesti - eesti - Ravimiamet

sodium chloride kabi 0,9% süsteravimi lahusti

fresenius kabi polska sp. z o.o. - naatriumkloriid - süsteravimi lahusti - 9mg 1ml 10ml 50tk; 9mg 1ml 20ml 20tk; 9mg 1ml 5ml 20tk; 9mg 1ml 5ml 50tk

SODIUM BICARBONATE BRAUN 8,4% infusioonilahus Eesti - eesti - Ravimiamet

sodium bicarbonate braun 8,4% infusioonilahus

b. braun melsungen ag - naatriumvesinikkarbonaat - infusioonilahus - 8,4% 250ml 10tk

SODIUM CHLORIDE BRAUN 5,85% infusioonilahuse kontsentraat Eesti - eesti - Ravimiamet

sodium chloride braun 5,85% infusioonilahuse kontsentraat

b. braun melsungen ag - naatriumkloriid - infusioonilahuse kontsentraat - 5,85% 20ml 20tk